Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $859,157 | 9 | 100.0% |
| Food and Beverage | $51.89 | 2 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $859,157 | 9 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $34.94 | 1 | $0 (2018) |
| Medtronic, Inc. | $16.95 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $859,174 | 10 | Amneal Pharmaceuticals LLC ($859,157) |
| 2018 | $34.94 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($34.94) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | — | Cash or cash equivalent | $359,896.80 | Research |
| Study: Supratherapeutic Dose of Carbidopa in Healthy Subjects • Category: NEUROLOGY | ||||||
| 07/17/2024 | Medtronic, Inc. | IN.PACT ADMIRAL (Device) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: Drug-Coated Balloons | ||||||
| 06/26/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | — | Cash or cash equivalent | $21,708.00 | Research |
| Study: A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects • Category: NEUROLOGY | ||||||
| 02/02/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | — | Cash or cash equivalent | $92,062.00 | Research |
| Study: A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects • Category: NEUROLOGY | ||||||
| 02/02/2024 | Amneal Pharmaceuticals LLC | — | — | Cash or cash equivalent | $92,062.00 | Research |
| Study: A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF CARBIDOPA IN HEALTHY SUBJECTS. | ||||||
| 02/02/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | — | Cash or cash equivalent | $67,512.00 | Research |
| Study: A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects • Category: NEUROLOGY | ||||||
| 02/02/2024 | Amneal Pharmaceuticals LLC | — | — | Cash or cash equivalent | $67,512.00 | Research |
| Study: A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF CARBIDOPA IN HEALTHY SUBJECTS. | ||||||
| 02/02/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | — | Cash or cash equivalent | $11,690.00 | Research |
| Study: A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects • Category: NEUROLOGY | ||||||
| 02/02/2024 | Amneal Pharmaceuticals LLC | — | — | Cash or cash equivalent | $11,690.00 | Research |
| Study: A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF CARBIDOPA IN HEALTHY SUBJECTS. | ||||||
| 01/12/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | — | Cash or cash equivalent | $135,024.00 | Research |
| Study: A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects • Category: NEUROLOGY | ||||||
| 10/08/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $34.94 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Supratherapeutic Dose of Carbidopa in Healthy Subjects | Amneal Pharmaceuticals LLC | $359,897 | 1 |
| A Three-Way Crossover Thorough QT/QTc Study to Evaluate the Electrocardiographic Effects of a Supratherapeutic Dose of Carbidopa in Healthy Subjects | Amneal Pharmaceuticals LLC | $327,996 | 5 |
| A THREE-WAY CROSSOVER THOROUGH QT/QTC STUDY TO EVALUATE THE ELECTROCARDIOGRAPHIC EFFECTS OF A SUPRATHERAPEUTIC DOSE OF CARBIDOPA IN HEALTHY SUBJECTS. | Amneal Pharmaceuticals LLC | $171,264 | 3 |
About Dr. John Mickelson, DO
Dr. John Mickelson, DO is a Family Medicine healthcare provider based in Lincoln City, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497773097.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Mickelson, DO has received a total of $859,209 in payments from pharmaceutical and medical device companies, with $859,174 received in 2024. These payments were reported across 11 transactions from 3 companies. The most common payment nature is "" ($859,157).
Practice Information
- Specialty Family Medicine
- Other Specialties Occupational Medicine, Family Medicine
- Location Lincoln City, OR
- Active Since 07/18/2006
- Last Updated 09/04/2025
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1497773097
Products in Payments
- CREXONT (Drug) $687,893
- IN.PACT ADMIRAL (Device) $16.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Lincoln City
William Cornish, Md, MD
Family Medicine — Payments: $1,699
Dr. Jerry Flaming, D.o, D.O
Family Medicine — Payments: $1,180
Marilyn Fraser, M.d, M.D
Family Medicine — Payments: $477.99
Lynn Athens, Md, MD
Family Medicine — Payments: $42.09
Dr. Robert Kaye, M.d, M.D
Family Medicine
Brian Handley, Md, MD
Family Medicine